Matson et al showed that, in melanoma patients who were administrated with PD‐1 antibody, responders had more abundant fecal bacterial species than non‐responders, and germ‐free mice transplanted with fecal bacteria from responding patients showed activated immune response and improved efficacy of anti‐PD‐L1 therapy.7 The gene discussed is RPL17; the disease is melanoma.